Table II.
Frequency of melanoma patients with IL-27 value above 500, 1000 and 5000 pg/mL
| Criteria | Stage | >500 pg/mL | >1000 pg/mL | >5000 pg/m L | |||
|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | ||
| Ia | (4/10) | 40 | (3/10) | 30 | (2/10) | 20 | |
| AJCC | Ib | (14/25) | 56 | (8/25) | 32 | (6/25) | 24 |
| IIa | (8/10) | 80 | (7/10) | 70 | (7/10) | 70 | |
| IIb | (2/7) | 29 | (2/7) | 29 | (1/7) | 14 | |
| IIc | (1/5) | 20 | (1/5) | 20 | (1/5) | 20 | |
| III | (4/11) | 36 | (1/11) | 9 | (0/11) | 0 | |
| IV | (1/4) | 25 | (0/4) | 0 | (0/4) | 0 | |
| PFI | <24 | (10/22) | 45 | (7/22) | 32 | (7/22) | 32 |
| >24 | (23/48) | 48 | (16/48) | 33 | (11/48) | 23 | |
| TNM | 1 | (18/35) | 51 | (11/35) | 31 | (8/35) | 23 |
| 2 | (11/22) | 50 | (10/22) | 45 | (9/22) | 41 | |
| 3 | (4/10) | 40 | (3/10) | 30 | (2/10) | 20 | |
| 4 | (1/5) | 20 | (0/5) | 0 | (0/5) | 0 | |
| Disease | I+II | (29/57) | 51 | (21/57) | 37 | (17/57) | 30 |
| Spread | III+IV | (5/12) | 42 | (3/12) | 25 | (2/12) | 17 |
| Control | (29/44) | 66 | (13/44) | 30 | (6/44) | 14 | |